Hundreds of pharmaceutical and biotech companies, including many Massachusetts organizations, have signed an open letter calling for a reversal of the Texas ban on Mifepristone. One of the letter’s signatories, Donna LaVoie, president & CEO of LaVoie Health Science, and Peter Pitts, president and co-founder of the Center for Medicine in the Public Interest, join Saraya Wintersmith to discuss the implications on future drug innovation. “Drugmakers will play it safe, which is not a good sign for breakthrough innovations like Alzheimer’s and ALS,” said Pitts.
